BTK and myeloid sarcoma: Finally, caution needs to be taken regarding the generalizability of the results about the potential inverse association between ibrutinib and epilepsy in patients with MS, given ibrutinib is used for lymphocytic malignancies, and there is yet no FDA-approved BTK inhibitor for MS.